{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:19Z","timestamp":1790936299475,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jaapos.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T09:48:57Z","timestamp":1512640137000},"page":"61-65.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity"],"prefix":"10.1016","volume":"22","author":[{"given":"Kathleen A.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Mintz-Hittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.jaapos.2017.10.006_bib2","first-page":"501","article-title":"An update on progress and the changing epidemiology of causes of childhood blindness worldwide","volume":"16","author":"Kong","year":"2012","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2017.10.006_bib3","doi-asserted-by":"crossref","first-page":"F179","DOI":"10.1136\/archdischild-2014-306207","article-title":"Impact of retinopathy of prematurity on ocular structures and visual functions","volume":"100","author":"Fielder","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.jaapos.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archopht.1996.01100130413008","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 5\u00bd years after randomization","volume":"114","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/archophthalmol.2011.143","article-title":"Grating visual acuity results in the Early Treatment for Retinopathy of Prematurity Study","volume":"129","author":"The Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2017.10.006_bib8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2017.10.006_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMe1100248","article-title":"Bevacizumab for retinopathy of prematurity","volume":"364","author":"Reynolds","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaapos.2017.10.006_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.semperi.2015.12.006","article-title":"Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity","volume":"40","author":"Beharry","year":"2016","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib12","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.jaapos.2017.10.006_bib13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2016.06.054","article-title":"Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system","volume":"123","author":"Good","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IFG-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaapos.2017.10.006_bib16","first-page":"1","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"0","author":"Wu","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2017.10.006_bib17","first-page":"S129","article-title":"Anti-vascular endothelial growth factor preparations in the treatment of retinopathy of prematurity: balancing risks and benefits","volume":"53","author":"Chawla","year":"2016","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.jaapos.2017.10.006_bib18","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"2","author":"Sankar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaapos.2017.10.006_bib19","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2017.10.006_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jaapos.2017.10.006_bib21","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaapos.2017.10.006_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib23","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2017.10.006_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm","volume":"92","author":"Papile","year":"1978","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaapos.2017.10.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-197801000-00001","article-title":"Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging","volume":"187","author":"Bell","year":"1978","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaapos.2017.10.006_bib27","series-title":"Bayley scales of infant and toddler development","year":"2006"},{"key":"10.1016\/j.jaapos.2017.10.006_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jpeds.2012.05.048","article-title":"Improving the Neonatal Research Network annual certification for neurologic examination of the 18-22 month child","volume":"161","author":"Newman","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaapos.2017.10.006_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1469-8749.1997.tb07414.x","article-title":"Development and reliability of a system to classify gross motor function in children with cerebral palsy","volume":"39","author":"Palisano","year":"1997","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jaapos.2017.10.006_bib30","first-page":"8","article-title":"A\u00a0report: the definition and classification of cerebral palsy","volume":"109","author":"Rosenbaum","year":"2007","journal-title":"Devel Med Child Neurol Suppl"},{"key":"10.1016\/j.jaapos.2017.10.006_bib32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jama.289.9.1124","article-title":"Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months","volume":"289","author":"Schmidt","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jaapos.2017.10.006_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jama.2013.282153","article-title":"Association between severe retinopathy of prematurity and nonvisual disabilities at age 5 years","volume":"311","author":"Schmidt","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaapos.2017.10.006_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpeds.2016.05.070","article-title":"Growth outcomes of preterm infants exposed to different oxygen saturation target ranges from birth","volume":"176","author":"Navarrete","year":"2016","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaapos.2017.10.006_bib35","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1208506","article-title":"Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial","volume":"367","author":"Vaucher","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaapos.2017.10.006_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.semperi.2016.05.011","article-title":"Changing definitions of long-term follow-up: should \u201clong-term\u201d be even longer?","volume":"40","author":"Hintz","year":"2016","journal-title":"Semin Perinatol"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853117305244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853117305244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:22:50Z","timestamp":1761078170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853117305244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1091853117305244"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2017.10.006","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}